Vir Biotechnology, Inc. (VIR)
11.70
+0.58
(+5.22%)
USD |
NASDAQ |
Oct 09, 16:00
11.49
-0.21
(-1.79%)
After-Hours: 05:05
Vir Biotechnology Shareholders Equity (Quarterly) : 982.49M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 982.49M |
| March 31, 2026 | 812.76M |
| December 31, 2025 | 765.28M |
| September 30, 2025 | 796.10M |
| June 30, 2025 | 947.47M |
| March 31, 2025 | 1.044B |
| December 31, 2024 | 1.150B |
| September 30, 2024 | 1.241B |
| June 30, 2024 | 1.434B |
| March 31, 2024 | 1.547B |
| December 31, 2023 | 1.590B |
| September 30, 2023 | 1.675B |
| June 30, 2023 | 1.810B |
| March 31, 2023 | 1.971B |
| December 31, 2022 | 2.078B |
| September 30, 2022 | 2.150B |
| Date | Value |
|---|---|
| June 30, 2022 | 1.952B |
| March 31, 2022 | 2.001B |
| December 31, 2021 | 1.432B |
| September 30, 2021 | 876.27M |
| June 30, 2021 | 737.32M |
| March 31, 2021 | 650.95M |
| December 31, 2020 | 716.85M |
| September 30, 2020 | 812.36M |
| June 30, 2020 | 563.78M |
| March 31, 2020 | 380.33M |
| December 31, 2019 | 423.94M |
| September 30, 2019 | -280.80M |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 129.96M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Moderna, Inc. | 6.761B |
| Vaxcyte, Inc. | 2.758B |
| Caribou Biosciences, Inc. | 98.10M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.215B |
| Total Liabilities (Quarterly) | 232.31M |
| Debt to Equity Ratio | 0.0949 |
| Current Ratio | 6.042 |
| Net Debt Paydown Yield | 0.03% |